LA JOLLA, CA--(Marketwired - Oct 20, 2016) - ActivX Biosciences, Inc., a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces two reports published in high profile, ...
Dual anti–human epidermal growth factor receptor 2 (HER2) therapy plus chemotherapy followed by maintenance treatment with HER2-targeted and endocrine therapies is standard first-line treatment for ...
Deregulation of the cell cycle machinery is a hallmark of cancer. While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen receptor-positive breast cancer, two major ...
Researchers showed the potential of combining 2 precision medicines to overcome treatment resistance. When palbociclib, a breast cancer drug, and crizotinib, a lung cancer drug, were used in ...
While existing drugs like palbociclib target CDK4/6, they eventually falter as tumors develop resistance, leaving few options for patients. Concarlo is taking a novel approach by targeting a central ...
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical ...
Using proton pump inhibitors (PPIs) during treatment with palbociclib (Ibrance) capsules was linked to higher risks of progression and death among patients with breast cancer, according to a ...
LA JOLLA, CA--(Marketwired - Oct 20, 2016) - ActivX Biosciences, Inc., a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces two reports published in high profile, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results